Who
Kristin Patrick
Director
Company insider
Files Form 4 as: Director, Laird Superfood; Director, Niagen Bioscience; Director, Super League Enterprise.
In numbers
- Trades disclosed
- 24
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $82K
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 3 Aug 2020
- Last trade
- 9 Jul 2026
- Last filed
- 13 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jul 2026filed 13 Jul 2026 | LSF Laird Superfoodoption or derivative · Food Products | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | LSF Laird Superfoodoption or derivative · Food Products | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | LSF Laird Superfoodoption or derivative · Food Products | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | LSF Laird Superfoodoption or derivative · Food Products | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | LSF Laird Superfoodoption or derivative · Food Products | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | LSF Laird Superfoodoption or derivative · Food Products | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —31,746 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —31,746 at $0.00 | filing |
| 20 Oct 2025filed 3 Mar 2026 | SLE Super League EnterpriseIT Services & Consulting | SEC FORM 4 Code A | —1,446 | filing |
| 1 Oct 2025filed 3 Mar 2026 | SLE Super League EnterpriseIT Services & Consulting | SEC FORM 4 Code A | —962 | filing |
| 24 Jun 2025filed 26 Jun 2025 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 23 Aug 2024filed 26 Aug 2024 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 23 Aug 2024filed 26 Aug 2024 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 23 Aug 2024filed 26 Aug 2024 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Code M | $4,9203,000 at $1.64 | filing |
| 23 Aug 2024filed 26 Aug 2024 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Code M | $33K20,000 at $1.67 | filing |
| 23 Aug 2024filed 26 Aug 2024 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Sold | $82K23,000 at $3.57 | filing |
| 20 Jun 2024filed 24 Jun 2024 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 7 Sep 2023filed 29 Apr 2024 | SLE Super League EnterpriseIT Services & Consulting | SEC FORM 4 Code A | —27,027 | filing |
| 15 Jun 2023filed 16 Jun 2023 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 16 Jun 2022filed 21 Jun 2022 | SLE Super League EnterpriseIT Services & Consulting | SEC FORM 4 Code A | —60,000 | filing |
News
No headline names them, or the companies they trade most, lately.